Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Status and phase: Completed; Phase 2

Conditions: Heart Failure, Congestive; Renal Insufficiency

Treatments: Drug: KW-3902IV

Study type: Interventional

Funder types: Industry

Identifiers

NCT00159614

CKI-203

Details and patient eligibility

About

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stable congestive heart failure
• Impaired renal function
• Taking oral loop diuretic

Exclusion criteria

• Acutely decompensated (unstable) and end stage heart failure
• Diuretics other than loop diuretics
• Pregnant or nursing
• Inability to follow instructions
• Participation in another clinical trial within past 30 days

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind